Article
The FDA has approved the expansion of the clinical trial of Anamed Inc.'s Perma-Vision intracorneal lens for the correction of hyperopia up to +6 D.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.